Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.39% of ...

TD Cowen analyst Andrew Kligerman upgraded Arthur J. Gallagher (AJG) to Buy from Hold with a price target of $377, up from $295, following the ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

TD Cowen analyst Josh Jennings maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) yesterday. The company’s shares closed ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

TD Cowen has recently reiterated Marathon Petroleum Corp (MPC) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 6, 2024, TD Cowen had reiterated the ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Coca-Cola (NYSE:KO) from Hold to Buy. Analyst ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Leidos Holdings (NYSE:LDOS) from Buy to Hold.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

After a turbulent year, things should calm for payers with the advent of a business-friendly Trump administration — though ...